Zapata Quantum completes oversubscribed $15M financing led by Triatomic Capital

Zapata Quantum, Inc.

$15M oversubscribed round led by Triatomic Capital; other strategic investors participated.
Financing marks final milestone of year-long restructuring; capital to scale platform and team.
Funds to be used to expand science, engineering, product, and commercial functions.
Company highlights quantum-enabled drug discovery research named Nature Biotechnology cover paper in Dec 2025.
Zapata focuses on hardware-agnostic quantum software, closing gap from experimentation to production.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.